Cannabis Use and Epigenetic Alterations in Human Male Sperm Cells
Cannabis Use and Epigenetic Alterations in Human Male Sperm Cells: Effects of Exposure and Abstinence (Component 1)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
North Carolina
-
Durham, North Carolina, United States, 27705
- Duke Child and Family Study Center
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Male gender
- Between the ages of 18-40 years, inclusive;
- Free from significant medical/psychiatric conditions
- Willingness to provide baseline semen sample and again at the end of study participation
- Willingness to comply
- Ability to communicate verbally and in written form in English.
For the CANNABIS USER group:
- Self-reported Cannabis use of at least once weekly for past 6 months;
- THC level of at least 50 ng/ml (EIA, non-creatinine adjusted value) and THCCOOH level of at least 15ng/ml (LCMSMS, non-creatinine adjusted value);
- Positive result on urine rapid screening test for THC; and
- Willingness to abstain from Cannabis for 11 weeks during the course of the study
For the CANNABIS NON-USER group:
- Self-report of no Cannabis use in the past 6 months; fewer than 10 times lifetime;
- THCCOOH level = 0 ng/ml; (EIA non-creatinine adjusted value) and
- Negative result on urine rapid screening test.
Exclusion Criteria:
- Positive result for any other drugs of abuse on urine rapid screening test (including cocaine, methamphetamine, opiates, benzodiazepines, and barbiturates); or use of nicotine or tobacco products;-Currently prescribed any psychoactive medication;
- Current diagnosis of any significant psychiatric condition, including substance use disorders. For the user group, Cannabis Use Disorder that does not require immediate clinical attention in the opinion of the clinician/investigator will be allowed.
- Score on the Marijuana Screening Inventory-X > 10;
- Score on the Alcohol Use Disorders Identification Test > 8;
- Expired breath CO reading of > 8 ppm at screening and throughout the study.
- Expired Breath Alcohol Level of > 0.000 at screening.
- Urinary cotinine level greater than 2- indicating urinary concentrations of > 30ng/ml cotinine at screening and throughout the study
- Estimated IQ < 80 as assessed by the Kaufman Brief Intelligence Test, Second Edition; and
- Unable to comply with study requirements or otherwise unsuitable for participation in the opinion of the study physician and/or study psychologist.
Study Plan
How is the study designed?
Design Details
- Observational Models: Other
- Time Perspectives: Prospective
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Cannabis User Group
Forty eight participants who are regular Cannabis users with a self-reported frequency of at least once weekly over the past 6 months of screening visit.
|
Cannabis user group will be asked to abstain from any form of Cannabis use for 11 weeks.
During their contingency management phase/abstinence phase, they will be required to come to the clinic for 25 visits over an 11 week period of abstinence.
|
|
Non-Cannabis User Group
Twenty four participants who self-report no Cannabis use in the past 6 months of screening visit and fewer than 10 times during their lifetime
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Group differences in sperm DNA methylation profiles between user and non-user group
Time Frame: Baseline
|
We will compare the overall DNA methylation profiles in sperm cells of user and non-user group to replicate findings in the pilot study.
|
Baseline
|
|
Within group change in DNA methylation profiles from baseline to after 11 weeks of Cannabis abstinence
Time Frame: Baseline to after 11 weeks of abstinence from Cannabis use.
|
We will compare the overall DNA methylation profiles in sperm cells after an 11 week period of Cannabis abstinence in the user group
|
Baseline to after 11 weeks of abstinence from Cannabis use.
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Group differences in the sperm analysis profile between user and non-user group
Time Frame: Baseline
|
We will compare the overall sperm analysis profile of user versus non-user group to replicate findings in the pilot study
|
Baseline
|
|
Within group change in sperm analysis profile from baseline to after eleven weeks of Cannabis abstinence
Time Frame: Baseline to after 11 weeks of abstinence from Cannabis use
|
We will compare sperm analysis profile after an eleven week period of Cannabis abstinence in the user group
|
Baseline to after 11 weeks of abstinence from Cannabis use
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- Pro00086400
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.